Encouraging Interim Data from a Phase 1 Clinical Study Evaluating MOv18 IgE in Cancer Patients with Advanced Solid Tumours Presented at the AACR Virtual Annual Meeting
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an
Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London,
Epsilogen Licences MOv18 IgE, an Anti-folate Receptor Alpha IgE Antibody from King’s College London
MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells
Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH
Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11 Data show, for the first time, that INDY inhibition attenuates
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM Mass., Jan. 13, 2020 – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously
Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients
“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin